Advanced Search

Subscribe to a Global-Regulation Premium Membership Today!

We are constantly working to improve the site, and to add more laws to our database. If you are receiving value from using our site please consider signing up for a subscription to support the site and to get many additional benefits for you.

Key Benefits:

  • Unlimited Searches
  • Weekly Updates on New Laws
  • Access to 5,345,848 Global Laws from 110 Countries
  • View the Original Law Side-by-Side with the Translation
  • No Ads

Subscribe Now for only USD$40 per month.

(You can close this ad by clicking anywhere on the page.)

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 7) (No. PB 65 of 2012)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
 
PB 65 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 7)
 
National Health Act 1953
___________________________________________________________________________
 
I, STEVE DUNLOP, Assistant Secretary A/g, Pharmaceutical Programs and Support Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 16 /8/2012
 
 
 
 
 
 
 
 
 
 
 
STEVE DUNLOP
Assistant Secretary A/g
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 7).
 
(2)                This Instrument may also be cited as PB 65 of 2012.
 
2             Commencement
                This Instrument commences on 1 September 2012.
3              Amendments to PB 79 of 2011
                 Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
 
 
[1]    Schedule 1 Part 1, entry for Docetaxel
omit:
Docetaxel
Injection set containing 1 single use vial concentrate for I.V. infusion 20mg (anhydrous) in 0.5 mL with solvent
 Injection
Taxotere
SW
MP
C3186 C3888 C3890 C3892 C3916 C3955
C3956
C7002
D

 
Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) in 2 mL with solvent
 Injection
Taxotere
SW
MP
C3186 C3888 C3890 C3892 C3916 C3955
C3956
C7002
D

substitute:
Docetaxel
Injection set containing 1 single use vial concentrate for I.V. infusion 80mg (anhydrous) in 2 mL with solvent
 Injection
Taxotere
SW
MP
C3186 C3888 C3890 C3892 C3916 C3955
C3956
C7002
D
 
[2]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’
Insert after C3890:
C3892
 
 
[3]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’
Insert after C3890:
C3892
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.